Cooke Julie

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences (NBIX), has been a consistent seller of company stock over the past year, with no open-market purchases recorded in her SEC Form 4 filings. Her most recent activity on June 2, 2026, shows five open-market sales totaling approximately $5.76 million, with individual transactions ranging from $558,235 to $2.2 million. These sales were paired with an option exercise valued at $2.03 million, a mechanical transaction that typically precedes a sale. Over the full reporting period, Cooke's total sell value reached $7.0 million across 39 filings, all concentrated in NBIX, with zero buy value — a pattern that indicates a clear divestment bias. The broader filing history reveals a mix of routine compensation-related transactions alongside the discretionary sales. In February 2026, Cooke received multiple stock awards (code A) valued at $0, which were accompanied by shares withheld to cover taxes (code F) totaling roughly $862,510. Similar award-and-withholding patterns appear in February 2025, along with smaller open-market sales of $88,183 and $92,946. A single option exercise in May 2025 worth $399,851 was not followed by a corresponding sale in the disclosed data, suggesting she may have held those shares. The June 2026 cluster, however, stands out as the largest single-day selling event, representing over 80% of her total sell value for the entire period. The transaction mix — heavy open-market sales, option exercises, and tax-withholding events, with no purchases — points to a consistent liquidation posture. Cooke's selling is concentrated in NBIX, her sole reported holding, and the June 2, 2026, sales alone dwarf her prior activity. While the exercise-and-sell pattern is common for executives monetizing vested options, the absence of any buy-side activity over the trailing year reinforces a one-directional trend. The data does not indicate whether these sales were pre-scheduled under a 10b5-1 plan, but the volume and timing suggest deliberate portfolio reduction rather than incidental transactions.